

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.



Abbisko Cayman Limited
和譽開曼有限責任公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT
CD73 INHIBITOR ABSK051 OBTAINED IND APPROVAL
FROM NMPA

Abbisko Cayman Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd. (“**Abbisko Therapeutics**”), a subsidiary of the Company, announced that its self-developed next-generation CD73 inhibitor ABSK051 has obtained the clinical trial approval from the National Medical Products Administration of the People’s Republic of China (“**NMPA**”). ABSK051 is about to enter the first-in-human (“**FIH**”) Phase I clinical trial for the treatment of advanced solid tumors in China.

This is a voluntary announcement made by the Company. The Group cannot guarantee that ABSK051 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, November 9, 2023

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Chen Zhui as executive directors; Ms. Tang Yanmin as a non-executive director; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Mr. Wang Lei as independent non-executive directors.

Abbisko Therapeutics Has Obtained the Clinical Trial Approval from NMPA for its Next-generation Small Molecule CD73 Inhibitor ABSK051

On November 9, 2023, Abbisko Therapeutics announced that its self-developed next-generation CD73 inhibitor ABSK051 has obtained the clinical trial approval from the NMPA. ABSK051 is about to enter the FIH Phase I clinical trial for the treatment of advanced solid tumors in China.

ABSK051 is a novel small molecule CD73 inhibitor with strong inhibition against CD73 enzymatic activity. In vitro and in vivo pharmacology data have demonstrated superior potency and selectivity of ABSK051 against CD73 with strong anti-tumor effects. In addition, the toxicological profile of ABSK051 has been well characterized in the preclinical safety assessment study.

About ABSK051-101

This is a FIH, multicenter, open-label Phase I clinical trial, which includes monotherapy dose escalation part and combination therapy dose escalation part. This study will evaluate the safety, tolerability, PK/PD, and preliminary antitumor activity of ABSK051 monotherapy in patients with any types of advanced solid tumors and ABSK051 in combination with tislelizumab in patients with selected tumor types, such as lung cancer, colorectal cancer (CRC), ovarian cancer, and pancreatic ductal adenocarcinoma (PDAC).

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Limited (Stock Code on the Hong Kong Stock Exchange: 2256.HK), is an oncology-focused biopharmaceutical company founded in Shanghai, dedicated to discovering and developing innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich R&D and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of 15 innovative small molecule programs focused on precision oncology and immuno-oncology, including eight clinical stage assets.

Please visit www.abbisko.com for more information.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.